Qilu Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 1992-08-21
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.qilu-pharma.com
Study on the Efficacy and Safety of QLM1016 in Schizophrenia
Phase 3
Not yet recruiting
- Conditions
- Schizophrenia
- Interventions
- Drug: 3-6mg QLM1016Drug: 10-20 mg Aripiprazole oral solution film
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 402
- Registration Number
- NCT06799559
a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.
Phase 3
Not yet recruiting
- Conditions
- Small-cell Lung Cancer
- Interventions
- Drug: Iparomlimab and Tuvonralimab (QL1706)Drug: placebo for QL1604Drug: placebo for Iparomlimab and Tuvonralimab (QL1706)
- First Posted Date
- 2025-01-23
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 636
- Registration Number
- NCT06789796
A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC
Phase 3
Recruiting
- Conditions
- NSCLC
- Interventions
- First Posted Date
- 2025-01-01
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 808
- Registration Number
- NCT06754644
- Locations
- 🇨🇳
Shandong First Medical University Cancer Hospital, Jinan, Shandong, China
Study of QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated LDL Cholesterol
Phase 2
Not yet recruiting
- Conditions
- Primary Hypercholesterolemia or Mixed Hyperlipidemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 156
- Registration Number
- NCT06750341
Monosialoganglioside in Acute Ischemic Stroke: a Randomized, Blinded and Multicenter Confirmatory Study
Phase 3
Completed
- Conditions
- Acute Ischemic Stroke
- Interventions
- Drug: MonosialogangliosideDrug: Placebo
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 1232
- Registration Number
- NCT06742216
- Locations
- 🇨🇳
Nanjing Gulou Medical College Affiliated Hospital, Nanjing, China
To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma
Phase 3
Not yet recruiting
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 284
- Registration Number
- NCT06742138
A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Phase 3
Not yet recruiting
- Conditions
- Triple-Negative Breast Cancer (TNBC)
- Interventions
- Drug: Investigator's Choice Chemotherapy
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 504
- Registration Number
- NCT06732323
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
A Study of Perioperative QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 288
- Registration Number
- NCT06686576
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Sun Yat-sen University, Guangzhou, China
Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Phase 3
Not yet recruiting
- Conditions
- Heavy Menstrual BleedingUterine Fibroids
- Interventions
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06671548
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
A Study of Olanzapine-Samidorphan Tablets in Adults With Schizophrenia
Phase 3
Not yet recruiting
- Conditions
- Schizophrenia
- Interventions
- Drug: Olanzapine-samidorphan；
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 654
- Registration Number
- NCT06649214